Skip to main content

Corticosteroids

  • Chapter

Summary

Corticosteroids are the most effective therapy for chronic immune and inflammatory diseases in current use. Despite their success over the past 50 years, and especially since the advent of new potent halogenated compounds, worries about the detrimental side-effects of systemic corticosteroids has limited their effectiveness in severe disease. This has resulted in the increasing use of TOPICAL corticosteroids targeted to the site of inflammation rather than systemic administration. Improvements in risk/benefit ratios are likely to occur, as greater understanding of the role of chemical substitutions of the synthetic corticosteroid becomes clear, and more potent tissue selective drugs are developed. Drugs that target distinct aspects of corticosteroid function, switching on or off genes, are also under development and along with non-steroidal agents that target different aspects of the inflammatory response are likely to lead to safer drugs with a much reduced side-effect profile. However, until these become widely available, current systemic and TOPICAL corticosteroids are likely to remain the major treatment for most inflammatory diseases.

Keywords

  • Fluticasone Propi
  • Allergy Clin Immunol
  • Topical Corticosteroid
  • Immune Thrombocytopenic Purpura
  • Beclomethasone Dipropionate

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/3-7643-7408-X_26
  • Chapter length: 15 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   84.99
Price excludes VAT (USA)
  • ISBN: 978-3-7643-7408-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected readings

  • Eggert M, Schulz M, Neeck G (2001) Molecular mechanisms of glucocorticoid action in rheumatic autoimmune diseases. J Steroid Biochem Mol Biol 77: 185–191

    CrossRef  PubMed  CAS  Google Scholar 

  • Friend DR (1998) Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 12: 591–603

    CrossRef  PubMed  CAS  Google Scholar 

  • Hofer KN (2003) Oral budesonide in the management of Crohn’s disease. Ann Pharmacother 37: 1457–1464

    CrossRef  PubMed  CAS  Google Scholar 

  • Leung DY, Bloom JW (2003) Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111: 3–22

    PubMed  CAS  CrossRef  Google Scholar 

  • Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96: 115–123

    CrossRef  PubMed  CAS  Google Scholar 

  • Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side-effects of glucocorticoids. Pharmacol Ther 96: 23–43

    CrossRef  PubMed  CAS  Google Scholar 

References

  1. Magiakou MA, Chrousos GP (2002) Cushing’s syndrome in children and adolescents: current diagnostic and therapeutic strategies. J Endocrinol Invest 25: 181–194

    PubMed  CAS  Google Scholar 

  2. Kino T, Vottero A, Charmandari E, Chrousos GP (2002) Familial/sporadic glucocorticoid resistance syndrome and hypertension. Ann NY Acad Sci 970: 101–111

    PubMed  CAS  CrossRef  Google Scholar 

  3. Barnes PJ, Adcock IM (2003) How do corticosteroids work in asthma? Ann Intern Med 139: 359–370

    PubMed  CAS  Google Scholar 

  4. Raju TN (1999) The Nobel chronicles. 1950: Edward Calvin Kendall (1886–1972); Philip Showalter Hench (1896–1965); and Tadeus Reichstein (1897–1996). Lancet 353: 1370

    PubMed  CAS  CrossRef  Google Scholar 

  5. Caramori G, Adcock I (2003) Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Ther 16: 247–277

    PubMed  CAS  CrossRef  Google Scholar 

  6. Johnson M (1996) Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 97: 169–176

    PubMed  CAS  CrossRef  Google Scholar 

  7. Brattsand R, Thalen A, Roempke K, Kallstrom L, Gruvstad E (1982) Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. J Steroid Biochem 16: 779–786

    CrossRef  PubMed  CAS  Google Scholar 

  8. Adcock IM (2003) Glucocorticoids: new mechanisms and future agents. Curr Allergy Asthma Rep 3: 249–257

    PubMed  CrossRef  Google Scholar 

  9. Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270: 286–290

    ADS  PubMed  CAS  CrossRef  Google Scholar 

  10. Shim J, Karin M (2002) The control of mRNA stability in response to extracellular stimuli. Mol Cells 14: 323–331

    PubMed  CAS  Google Scholar 

  11. Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schutz G (2001) Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 20: 7168–7173

    CrossRef  PubMed  CAS  Google Scholar 

  12. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P et al (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93: 531–541

    CrossRef  PubMed  CAS  Google Scholar 

  13. Norman AW, Mizwicki MT, Norman DP (2004) Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3: 27–41

    CrossRef  PubMed  CAS  Google Scholar 

  14. Buttgereit F, Scheffold A (2002) Rapid glucocorticoid effects on immune cells. Steroids 67: 529–534

    CrossRef  PubMed  CAS  Google Scholar 

  15. Croxtall JD, Van Hal PT, Choudhury Q, Gilroy DW, Flower RJ (2002) Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol 135: 511–519

    CrossRef  PubMed  CAS  Google Scholar 

  16. Leung DY, Bloom JW (2003) Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111: 3–22

    PubMed  CAS  CrossRef  Google Scholar 

  17. Eggert M, Schulz M, Neeck G (2001) Molecular mechanisms of glucocorticoid action in rheumatic autoimmune diseases. J Steroid Biochem Mol Biol 77: 185–191

    CrossRef  PubMed  CAS  Google Scholar 

  18. Morand EF (1998) Corticosteroids in the treatment of rheumatologic diseases. Curr Opin Rheumatol 10: 179–183

    PubMed  CAS  CrossRef  Google Scholar 

  19. Adcock IM, Chung KF (2002) Overview: why are corticosteroids ineffective in COPD? Curr Opin Investig Drugs 3: 58–60

    PubMed  CAS  Google Scholar 

  20. Huber MR, Kumar S, Tefferi A (2003) Treatment advances in adult immune thrombocytopenic purpura. Ann Hematol 82: 723–737

    CrossRef  PubMed  CAS  Google Scholar 

  21. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A (1981) Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med 304: 5–9

    PubMed  CAS  CrossRef  Google Scholar 

  22. Wilson JW, Djukanovic R, Howarth PH, Holgate ST (1994) Inhaled beclomethasone dipropionate down-regulates airway lymphocyte activation in atopic asthma. Am J Respir Crit Care Med 149: 86–90

    PubMed  CAS  Google Scholar 

  23. Schleimer RP, Bochner BS (1994) The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol 94: 1202–1213

    CrossRef  PubMed  CAS  Google Scholar 

  24. Redington AE, Wilson JW, Walls AF, Madden J, Djukanovic R, Holgate ST, Howarth PH (2000) Persistent airway T-lymphocyte activation in chronic corticosteroid-treated symptomatic asthma. Ann Allergy Asthma Immunol 85: 501–507

    PubMed  CAS  CrossRef  Google Scholar 

  25. in’t Veen JC, Smits HH, Hiemstra PS, Zwinderman AE, Sterk PJ, Bel EH (1999) Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med 160: 93–99

    PubMed  CAS  Google Scholar 

  26. Orsida BE, Li X, Hickey B, Thien F, Wilson JW, Walters EH (1999) Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 54: 289–295

    PubMed  CAS  CrossRef  Google Scholar 

  27. Brieva JL, Danta I, Wanner A (2000) Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma. Am J Respir Crit Care Med 161: 293–296

    PubMed  CAS  Google Scholar 

  28. Arend WP (2002) The mode of action of cytokine inhibitors. J Rheumatol (Suppl) 65: 16–21

    CAS  Google Scholar 

  29. Taylor PC (2003) Anti-TNFalpha therapy for rheumatoid arthritis: an update. Intern Med 42: 15–20

    PubMed  CAS  CrossRef  Google Scholar 

  30. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52: 998–1002

    CrossRef  PubMed  CAS  Google Scholar 

  31. John M, Lim S, Seybold J, Jose P, Robichaud A, O’Connor B, Barnes PJ, Chung KF (1998) Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med 157: 256–262

    PubMed  CAS  Google Scholar 

  32. Sousa AR, Trigg CJ, Lane SJ, Hawksworth R, Nakhosteen JA, Poston RN, Lee TH (1997) Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1ra) expression in asthmatic bronchial epithelium. Thorax 52: 407–410

    PubMed  CAS  CrossRef  Google Scholar 

  33. McMillan RM (2001) Leukotrienes in respiratory disease. Paediatr Respir Rev 2: 238–244

    CrossRef  PubMed  CAS  Google Scholar 

  34. Thomas E, Leroux JL, Blotman F, Descomps B, Chavis C (1995) Enhancement of leukotriene A4 biosynthesis in neutrophils from patients with rheumatoid arthritis after a single glucocorticoid dose. Biochem Pharmacol 49: 243–248

    CrossRef  PubMed  CAS  Google Scholar 

  35. Zaitsu M, Hamasaki Y, Aoki Y, Miyazaki S (2001) A novel pharmacologic action of glucocorticosteroids on leukotriene C4 catabolism. J Allergy Clin Immunol 108: 122–124

    CrossRef  PubMed  CAS  Google Scholar 

  36. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM (1999) Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 45: 382–388

    PubMed  CAS  CrossRef  Google Scholar 

  37. Norman M, Hearing SD (2002) Glucocorticoid resistance — what is known? Curr Opin Pharmacol 2: 723–729

    PubMed  CAS  CrossRef  Google Scholar 

  38. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC (2002) Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 57: 226–230

    CrossRef  PubMed  CAS  Google Scholar 

  39. Pickup ME (1979) Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 4: 111–128

    PubMed  CAS  CrossRef  Google Scholar 

  40. Swartz SL, Dluhy RG (1978) Corticosteroids: clinical pharmacology and therapeutic use. Drugs 16: 238–255

    PubMed  CAS  CrossRef  Google Scholar 

  41. Colice GL (2000) Comparing inhaled corticosteroids. Respir Care 45: 846–853

    PubMed  CAS  Google Scholar 

  42. Edsbacker S (1999) Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 58(Suppl 4): 7–16

    PubMed  CAS  CrossRef  Google Scholar 

  43. Lundin PD, Edsbacker S, Bergstrand M, Ejderhamn J, Linander H, Hogberg L, Persson T, Escher JC, Lindquist B (2003) Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn’s disease. Aliment Pharmacol Ther 17: 85–92

    CrossRef  PubMed  CAS  Google Scholar 

  44. Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side-effects of glucocorticoids. Pharmacol Ther 96: 23–43

    CrossRef  PubMed  CAS  Google Scholar 

  45. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96: 115–123

    CrossRef  PubMed  CAS  Google Scholar 

  46. Robertson DB, Maibach HI (1982) Topical corticosteroids. Int J Dermatol 21: 59–67

    PubMed  CAS  CrossRef  Google Scholar 

  47. Schacke H, Hennekes H, Schottelius A, Jaroch S, Lehmann M, Schmees N, Rehwinkel H, Asadullah K (2002) SEGRAs: a novel class of anti-inflammatory compounds. Ernst Schering Res Found Workshop 357–371

    Google Scholar 

  48. Charman C, Williams H (2003) The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 21: 193–200

    PubMed  CrossRef  Google Scholar 

  49. Friend DR (1998) Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 12: 591–603

    CrossRef  PubMed  CAS  Google Scholar 

  50. Sandborn WJ, Feagan BG (2003) Review article: mild to moderate Crohn’s disease — defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 18: 263–277

    CrossRef  PubMed  CAS  Google Scholar 

  51. Cui N, Friend DR, Fedorak RN (1994) A budesonide prodrug accelerates treatment of colitis in rats. Gut 35: 1439–1446

    PubMed  CAS  CrossRef  Google Scholar 

  52. Brattsand R, Linden M (1996) Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 10(Suppl 2): 81–90

    PubMed  CAS  Google Scholar 

  53. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG (2002) The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther 16: 1509–1517

    CrossRef  PubMed  CAS  Google Scholar 

  54. Hofer KN (2003) Oral budesonide in the management of Crohn’s disease. Ann Pharmacother 37: 1457–1464

    CrossRef  PubMed  CAS  Google Scholar 

  55. Ioannou Y, Isenberg DA (2002) Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 78: 599–606

    CrossRef  PubMed  CAS  Google Scholar 

  56. Pizzuto J, Ambriz R (1984) Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 64: 1179–1183

    PubMed  CAS  Google Scholar 

  57. Barnes PJ (1990) Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis 141: S70–S76

    PubMed  CAS  Google Scholar 

  58. van den BM, Kerstjens HA, Meijer RJ, de Reus DM, Koeter GH, Kauffman HF, Postma DS (2001) Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 164: 1127–1132

    PubMed  Google Scholar 

  59. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Selroos O, Sovijarvi A et al (1994) Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 331: 700–705

    CrossRef  PubMed  CAS  Google Scholar 

  60. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side-effects. Proc Natl Acad Sci USA 101: 227–232

    ADS  PubMed  CrossRef  Google Scholar 

  61. Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R et al (1996) Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 110: 1713–1718

    CrossRef  PubMed  CAS  Google Scholar 

  62. de Kaski MC, Peters AM, Lavender JP, Hodgson HJ (1991) Fluticasone propionate in Crohn’s disease. Gut 32: 657–661

    PubMed  CrossRef  Google Scholar 

  63. Kanniess F, Richter K, Bohme S, Jorres RA, Magnussen H (2001) Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 14: 141–147

    PubMed  CAS  CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2005 Birkhäuser Verlag

About this chapter

Cite this chapter

Adcock, I.M., Ito, K. (2005). Corticosteroids. In: Nijkamp, F.P., Parnham, M.J. (eds) Principles of Immunopharmacology. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7408-X_26

Download citation